<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01565343</url>
  </required_header>
  <id_info>
    <org_study_id>18F-AV-45-A04</org_study_id>
    <nct_id>NCT01565343</nct_id>
  </id_info>
  <brief_title>A Study of 18F-AV-45 in Alzheimer's Disease (AD) and Healthy Volunteers</brief_title>
  <official_title>Test-retest Reproducibility of 18F-AV-45 for Brain Imaging of Amyloid in Healthy Volunteers and Alzheimer's Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avid Radiopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Avid Radiopharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test if two AV-45 PET scans up to 4 weeks apart in AD subjects and healthy
      volunteers provide the same results. The study will also test two different AV-45 injection
      methods in a small subgroup of enrolled AD subjects (slow vs. fast bolus group).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Cortical to Cerebellum SUVR</measure>
    <time_frame>50-70 min after injection</time_frame>
    <description>Standardized Uptake Value ratio (SUVR) is the ratio of tracer uptake in predefined cortical regions, relative to uptake in the whole cerebellum.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>AD Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two bolus IV injections followed by brain PET scan up to 4 weeks apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AD Subjects: Slow vs. Fast Bolus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two bolus IV injections followed by a brain PET scan up to 4 weeks apart.
The first injection given as a rapid bolus (&lt; 5 second injection, with immediate flush). The second injection given as a slow bolus (approximately 20 to 30 second injection with a flush delayed by 10 seconds after dose administration).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy male or female subjects; 35-55 years old. Two bolus IV injections followed by brain PET scan up to 4 weeks apart</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>florbetapir F 18</intervention_name>
    <description>IV injection, 370MBq (10mCi)</description>
    <arm_group_label>AD Subjects</arm_group_label>
    <arm_group_label>AD Subjects: Slow vs. Fast Bolus</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
    <other_name>18F-AV-45</other_name>
    <other_name>Amyvid</other_name>
    <other_name>florbetapir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (AD group):

          -  Greater than 50 years of age

          -  Probable AD according to the National Institute of Neurological and Communication
             Disorders and Stroke-Alzheimer's Disease and Related Disorders Association
             (NINCDS-ADRDA) criteria

          -  Mild/moderate dementia as evidenced by a Mini-Mental State Examination (MMSE) score
             ranging from 10 to 24, boundaries included, at screening

          -  History of cognitive decline gradual in onset and progressive over a period of at
             least 6 months

        Inclusion Criteria (healthy volunteer group):

          -  35 to 55 years of age, inclusive

          -  MMSE of 29 or greater

        Exclusion Criteria (both groups):

          -  Neurodegenerative disorders other than AD, including, but not limited to Parkinson's
             disease, Pick's disease, fronto-temporal dementia, Huntington's chorea, Down syndrome,
             Creutzfeldt-Jacob disease, normal pressure hydrocephalus, and progressive supranuclear
             palsy

          -  Diagnosis of other dementing / neurodegenerative disease

          -  Diagnosis of mixed dementia

          -  Cognitive impairment resulting from trauma, hypoxic damage, vitamin deficiency, brain
             infection, brain cancer, endocrine disease, or mental retardation

          -  Clinically significant infarct or possible multi-infarct dementia as defined by the
             NINCDS criteria

          -  Evidence on screening MRI or other biomarker that suggests alternate etiology for
             cognitive deficit (for healthy controls, evidence suggesting the presence of AD
             pathology)

          -  Clinically significant psychiatric disease

          -  History of epilepsy or convulsions

          -  Clinically significant hepatic, renal, pulmonary, metabolic, or endocrine disturbances

          -  Current clinically significant cardiovascular disease

          -  Received investigational medication within the last 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chief Medical Officer</last_name>
    <role>Study Director</role>
    <affiliation>Avid Radiopharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hallandale Beach</city>
        <state>Florida</state>
        <zip>33009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>North East</city>
        <state>Maryland</state>
        <zip>21901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2012</study_first_submitted>
  <study_first_submitted_qc>March 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2012</study_first_posted>
  <results_first_submitted>April 6, 2012</results_first_submitted>
  <results_first_submitted_qc>April 6, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 2, 2012</results_first_posted>
  <last_update_submitted>May 8, 2012</last_update_submitted>
  <last_update_submitted_qc>May 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amyloid imaging</keyword>
  <keyword>Positron Emission Tomography</keyword>
  <keyword>18F-AV-45</keyword>
  <keyword>florbetapir F 18</keyword>
  <keyword>Diagnostic imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>AD Subjects</title>
          <description>Male or female subjects &gt; 50 years old; probable AD according to NINCDS-ADRDA criteria; MMSE 10-24</description>
        </group>
        <group group_id="P2">
          <title>AD Subjects: Slow vs. Fast Bolus Group</title>
          <description>Same inclusion criteria as AD subjects. The first injection given as a rapid bolus (&lt; 5 second injection, with immediate flush). The second injection given as a slow bolus (approximately 20 to 30 second injection with a flush delayed by 10 seconds after dose administration).</description>
        </group>
        <group group_id="P3">
          <title>Control Subjects</title>
          <description>Healthy male or female subjects; 35-55 years old; no evidence of cognitive impairment; MMSE 29 or higher</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Administrative decision/technical issues</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AD Subjects</title>
          <description>Male or female subjects &gt; 50 years old; probable AD according to NINCDS-ADRDA criteria; MMSE 10-24</description>
        </group>
        <group group_id="B2">
          <title>AD Subjects: Slow vs. Fast Bolus Group</title>
          <description>Same inclusion criteria as AD subjects. The first injection given as a rapid bolus (&lt; 5 second injection, with immediate flush). The second injection given as a slow bolus (approximately 20 to 30 second injection with a flush delayed by 10 seconds after dose administration).</description>
        </group>
        <group group_id="B3">
          <title>Control Subjects</title>
          <description>Healthy male or female subjects; 35-55 years old; no evidence of cognitive impairment; MMSE 29 or higher</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.7" spread="10.66"/>
                    <measurement group_id="B2" value="79.0" spread="3.56"/>
                    <measurement group_id="B3" value="44.4" spread="5.64"/>
                    <measurement group_id="B4" value="61.1" spread="16.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Cortical to Cerebellum SUVR</title>
        <description>Standardized Uptake Value ratio (SUVR) is the ratio of tracer uptake in predefined cortical regions, relative to uptake in the whole cerebellum.</description>
        <time_frame>50-70 min after injection</time_frame>
        <population>Due to poor subject positioning that resulted in an incomplete brain image on the retest image day, accurate quantitative analysis for one healthy control was not possible, and the subject was excluded from the SUVR-based analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>AD Subjects</title>
            <description>Male or female subjects &gt; 50 years old; probable Alzheimer's Disease) AD according to National Institute of Neurological and Communication Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria; Mini-Mental State Examination (MMSE) 10-24</description>
          </group>
          <group group_id="O2">
            <title>Control Subjects</title>
            <description>Healthy male or female subjects; 35-55 years old; no evidence of cognitive impairment; MMSE 29 or higher</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Cortical to Cerebellum SUVR</title>
          <description>Standardized Uptake Value ratio (SUVR) is the ratio of tracer uptake in predefined cortical regions, relative to uptake in the whole cerebellum.</description>
          <population>Due to poor subject positioning that resulted in an incomplete brain image on the retest image day, accurate quantitative analysis for one healthy control was not possible, and the subject was excluded from the SUVR-based analyses.</population>
          <units>SUVR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Test (50-70 min)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.416" spread="0.245"/>
                    <measurement group_id="O2" value="1.005" spread="0.055"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Retest (50-70 min)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.407" spread="0.269"/>
                    <measurement group_id="O2" value="1.007" spread="0.061"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Intra-class Correlation Coefficient (ICC) of AD subjects 50-70 min test vs. retest values</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ICC</param_type>
            <param_value>0.9893</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Intra-class Correlation Coefficient of Control subjects 50-70 min test vs. retest values</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ICC</param_type>
            <param_value>0.9574</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Intra-subject variability (% difference) of AD subjects 50-70 min test vs. retest values</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean % difference</param_type>
            <param_value>2.35</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.413</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Intra-subject variability (% difference) of control subjects 50-70 min test vs. retest values</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean % difference</param_type>
            <param_value>1.49</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.839</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs reported within 7 days of injection. SAEs reported within 30 days of injection.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>AD Subjects</title>
          <description>Male or female subjects &gt; 50 years old; probable AD according to NINCDS-ADRDA criteria; MMSE 10-24</description>
        </group>
        <group group_id="E2">
          <title>AD Subjects: Slow vs. Fast Bolus Group</title>
          <description>Same inclusion criteria as AD subjects. The first injection given as a rapid bolus (&lt; 5 second injection, with immediate flush). The second injection given as a slow bolus (approximately 20 to 30 second injection with a flush delayed by 10 seconds after dose administration).</description>
        </group>
        <group group_id="E3">
          <title>Control Subjects</title>
          <description>Healthy male or female subjects; 35-55 years old; no evidence of cognitive impairment; MMSE 29 or higher</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>SUPRAVENTRICULAR EXTRASYSTOLES</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>VENTRICULAR EXTRASYSTOLES</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DYSGEUSIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Avid Radiopharmaceuticals</organization>
      <phone>215-298-0700</phone>
      <email>clinicaloperations@avidrp.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

